REPLICor Inc.

25 articles about REPLICor Inc.

• REPLICor Inc. Announces Publication Of Its REP 301 Study In HBV / HDV Co-Infection In The Lancet Gastroenterology & Hepatology

  9/28/2017

• REPLICor Inc. Discloses Achievement Of 1 Year Functional Control Of HBV And HDV With Naps And New Mechanistic Insights In NAP Pharmacology

  4/20/2017

• REPLICor Inc. Discloses Updated REP 401 Clinical Data At APASL 2017

  2/10/2017

• REPLICor Inc. Discloses Late Breaking HBV And Follow-Up HBV / HDV Clinical Data At AASLD 2016

  11/15/2016

• REPLICor Inc. To Disclose Late Breaking HBV Clinical Data At American Association for Study of Liver Diseases 2016

  10/4/2016

• REPLICor Inc. Announces Publication Of Its REP 101 And REP 102 Studies Demonstrating The Therapeutic Effect Of Naps And The Achievement Of Functional Control Off Treatment In Human Patients With Chronic Hepatitis B Infection

  6/7/2016

• REPLICor Inc. To Make Three Presentations At EASL 2016

  4/4/2016

• REPLICor Inc. To Present Pre-Clinical And Updated Clinical Data On REP 2139-Ca Based Combination Therapy In Chronic HBV And HBV / HDV Co-Infection At APASL 2016

  2/16/2016

• REPLICor Inc. To Present Pre-Clinical And Clinical Data On REP 2139-Ca Based Combination Therapy In Chronic HBV / HDV Co-Infection At HEPDART 2015

  12/1/2015

• REPLICor Inc. Discloses Continued Improvement Of The Antiviral Response In Patients With HBV / HDV Co-Infection Receiving REP 2139-Ca Based Combination Therapy

  11/16/2015

• REPLICor Inc. Announces Publication Of Its Pre-Clinical Data On The Therapeutic Effect Of Naps On Hepatitis B Virus Infection

  11/12/2015

• REPLICor Inc. Announces Grant Of US Patents On HBV / HDV Treatment Methods Combining HBsAg Reduction And Immunotherapy

  11/9/2015

• REPLICor Inc. To Present An Update On The Safety And Efficacy Of REP 2139-Ca Based Combination Therapy In Chronic HBV / HDV Co-Infection At American Association for Study of Liver Diseases 2015

  11/3/2015

• REPLICor Inc. Presents Updated Mechanistic Data And Pre-Clinical Interferon-Free Combination Treatment Data In HBV And HBV / HDV Co-Infection

  10/15/2015

• REPLICor Inc. Announces Initiation Of Recruitment For Its Phase IIb Clinical Trial With REP 2139-Mg Or REP 2165-Mg In Combination With Viread And Pegasys Or Zadaxin In Patients With Hbeag Negative Chronic Hepatitis B Infection

  10/5/2015

• REPLICor Inc. To Participate At The 6th DIA / FDA Oligonucleotide-Based Therapeutics Conference

  9/3/2015

• REPLICor Inc. To Participate In The Jefferies and Co. Hepatitis B Summit In Boston

  7/28/2015

• REPLICor Inc. Discloses Updated Clinical Trial Data To The Global Virus Hepatitis Summit In Berlin

  6/30/2015

• REPLICor Inc. To Present At The Israel Association For The Study Of Liver Conference And The Global Virus Hepatitis Summit In Berlin In June

  6/10/2015

• REPLICor Inc. Release: Significant Reduction Of HBsAg And HDV RNA By REP 2139-Ca In Caucasian Patients With HBV / HDV Co-Infection

  4/29/2015